U.S. markets close in 6 hours 13 minutes
  • S&P 500

    +9.54 (+0.22%)
  • Dow 30

    +144.22 (+0.42%)
  • Nasdaq

    +36.90 (+0.26%)
  • Russell 2000

    +5.90 (+0.25%)
  • Crude Oil

    +0.28 (+0.38%)
  • Gold

    +10.20 (+0.57%)
  • Silver

    +0.22 (+0.83%)

    +0.0034 (+0.29%)
  • 10-Yr Bond

    -0.0020 (-0.13%)

    -0.0008 (-0.06%)

    -0.2650 (-0.24%)

    -1,037.41 (-3.05%)
  • CMC Crypto 200

    -53.14 (-6.31%)
  • FTSE 100

    +26.64 (+0.37%)
  • Nikkei 225

    +190.95 (+0.66%)

Mediclinic International (LON:MDC) Share Prices Have Dropped 61% In The Last Three Years

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

Investing in stocks inevitably means buying into some companies that perform poorly. But long term Mediclinic International plc (LON:MDC) shareholders have had a particularly rough ride in the last three year. So they might be feeling emotional about the 61% share price collapse, in that time. The more recent news is of little comfort, with the share price down 25% in a year. On the other hand the share price has bounced 6.2% over the last week. But this could be related to the strong market, with stocks up around 2.6% in the same time.

Check out our latest analysis for Mediclinic International

There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

We know that Mediclinic International has been profitable in the past. However, it made a loss in the last twelve months, suggesting profit may be an unreliable metric at this stage. Other metrics might give us a better handle on how its value is changing over time.

Revenue is actually up 3.4% over the three years, so the share price drop doesn't seem to hinge on revenue, either. This analysis is just perfunctory, but it might be worth researching Mediclinic International more closely, as sometimes stocks fall unfairly. This could present an opportunity.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).


We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. If you are thinking of buying or selling Mediclinic International stock, you should check out this free report showing analyst profit forecasts.

A Different Perspective

Mediclinic International shareholders are down 24% for the year, falling short of the market return. Meanwhile, the broader market slid about 10%, likely weighing on the stock. Unfortunately, the longer term story isn't pretty, with investment losses running at 17% per year over three years. We would want clear information suggesting the company will grow, before taking the view that the share price will stabilize. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Mediclinic International (at least 1 which doesn't sit too well with us) , and understanding them should be part of your investment process.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on GB exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.